Publication date: Jul 05, 2023
Antiplatelet therapy plays a crucial role in a number of cardiovascular disorders. We currently have a range of antiplatelet agents in our armamentarium. In this review, we aim to summarise the common antiplatelet agents currently available, and their use in clinic practice. We not only highlight recent trials exploring antiplatelet therapy in atherosclerotic cardiovascular disease, but also in trials related to transcatheter aortic valve implantation and coronavirus disease 2019. Inevitably, the antithrombotic benefits of these drugs are accompanied by an increase in bleeding complications. Therefore, an individualised approach to weighing each patient’s thrombotic risk versus bleeding risk is imperative, in order to improve clinical outcomes.
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | cardiovascular disease |
| disease | MESH | coronavirus disease 2019 |
| disease | MESH | bleeding |
| disease | MESH | complications |
| disease | MESH | vascular disease |
| disease | MESH | heart disease |
| disease | MESH | acute coronary syndrome |
| disease | MESH | stroke |
| disease | MESH | peripheral vascular disease |
| drug | DRUGBANK | Coenzyme M |
| disease | VO | dose |
| drug | DRUGBANK | Acetylsalicylic acid |